OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced it was granted an End of ...
Company will be seeking alignment to begin rolling BLA submission NEW YORK--(BUSINESS WIRE)-- OS Therapies (OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback